Get the Stockscreener App
1.45
0.68%
-0.01
After Hours:
1.4501
0.000100
+0.01%
Cyclo Therapeutics Inc stock is currently priced at $1.45, with a 24-hour trading volume of 29,137.
It has seen a -0.68% decreased in the last 24 hours and a +6.62% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.43 pivot point. If it approaches the $1.51 resistance level, significant changes may occur.
Previous Close:
$1.46
Open:
$1.53
24h Volume:
29,137
Market Cap:
$42.85M
Revenue:
$951.80K
Net Income/Loss:
$-19.40M
P/E Ratio:
-0.7713
EPS:
-1.88
Net Cash Flow:
$-14.64M
1W Performance:
+11.54%
1M Performance:
+6.62%
6M Performance:
+50.35%
1Y Performance:
+21.85%
1D Range:
$1.45
$1.57
52W Range:
$0.8924
$2.57
Cyclo Therapeutics Inc Stock (CYTH) Company Profile
Name
Cyclo Therapeutics Inc
Sector
Phone
386 418 8060
Address
6714 NW 16th Street, Suite B, Gainesville
Cyclo Therapeutics Inc Stock (CYTH) Latest News
Cyclo Therapeutics Inc Stock (CYTH) Financials Data
Cyclo Therapeutics Inc (CYTH) Revenue 2024
CYTH reported a revenue (TTM) of $951.80 thousand for the quarter ending September 30, 2023, a -46.35% decline year-over-year.
Cyclo Therapeutics Inc (CYTH) Net Income 2024
CYTH net income (TTM) was -$19.40 million for the quarter ending September 30, 2023, a -46.24% decrease year-over-year.
Cyclo Therapeutics Inc (CYTH) Cash Flow 2024
CYTH recorded a free cash flow (TTM) of -$14.64 million for the quarter ending September 30, 2023, a +2.38% increase year-over-year.
Cyclo Therapeutics Inc (CYTH) Earnings per Share 2024
CYTH earnings per share (TTM) was -$1.67 for the quarter ending September 30, 2023, a -5.70% decline year-over-year.
About Cyclo Therapeutics Inc
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
0.15%
1.40%
Cap:
|
Volume (24h):